Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
摘要
Low-molecular weight gadolinium (Gd)-based MR contrast agents for PSMA- specific Ti-weighted MR imaging are disclosed. The (Gd)-based MR contrast agents exhibit high binding affinity for PSMA and exhibit specific Ti contrast enhancement at PSMA+ cells. The PSMA-targeted Gd-based MR contrast agents can be used for PSMA- targeted imaging in vivo. 86Y-labeled PSMA-binding ureas also are provided, wherein the PSMA-binding ureas also are suitable for use with other radiotherapeutics.
申请公布号
AU2015256002(A1)
申请公布日期
2016.12.22
申请号
AU20150256002
申请日期
2015.05.06
申请人
Northwestern University;The Johns Hopkins University
发明人
Ray, Sangeeta;Pomper, Martin G.;Meade, Thomas J.;Mease, Ronnie C.;Chen, Ying;Yang, Xing;Rotz, Matthew